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Figure 2. FLT medullary uptake during myeloablation and marrow
repopulation
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myeloablative HSCT for leukemia. Images analyzed included:
1) after ablation (day-1) evaluating for residual hematopoi-
esis, 2) early engraftment after HSCT (day +5-12), and 3) 28
days after HSCT, full marrow reconstitution. The algorithm
sensitively excluded uptake from non-marrow sources by
means of a CT mask that identiﬁed bone structures and
measured the total functional volume within the axial skel-
eton (Figure 1). Spinal and pelvic medullary volumes from CT
mask were median of 586.6 mL (range 400.9- 808.2 mL) and
a median of 860.2 mL (range 592.8-1054.1ml) respectively.
As expected, CT generated volume correlated signiﬁcantly
with height (cm) in spine (p¼.0002, R2¼0.62) and pelvis
(p¼.0125, R2¼0.37), and ideal body weight (kg) in spine
(p<.0001, R2¼0.74) and pelvis (p¼.0012, R2¼0.54). SUV
ranged from 0.6 to 4; marrowactivity was deﬁned> than 1.2,
per published literature. All patients were neutropenic
following HSCT, engrafted in the expected time frame, and
showed full donor chimerism. After myeloablation in the 14
non-relapse patients, less than 2% of the axial skeleton
demonstrated activity (range <1%-13%). By day 5-6 after
HSCT, this increased 8-fold to 17%(range 1%-28%), and it
increased by 36-fold by day 9-12 to 72%(range 56%-89%).
After 28 days, repopulated marrow showed proliferative
activity of 96% (81-99%) (p<0.02 between all 4 time points).
In summary, using a semi-automated analysis of 18FLT up-
take, we show that hematopoiesis of entire axial skeleton
with a single image, which also correlates with height and
ideal body weight, suggesting that this is an accurate and
sensitive assessment of the medullary space. Further, we
show that imaging may assess the degree of myeloablation
after HSCT, and that SUV can describe the degree of marrow
engraftment. Our data show that 18FLT could reveal failure of
myeloablation and engraftment failure within 5-6 days of
HSCT, which could be used to direct novel therapies and
improve outcomes.463
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The beneﬁcial application of regulatory T cells (Treg:
CD4+CD25+FoxP3+) for suppression of GVHD following allo-
geneic HSCTcontinues to evolve. Because of the challenges to
expand large numbers of these cells ex-vivo prior to trans-
plant, strategies to manipulate the compartment in situ
would represent a signiﬁcant advance for therapeutic
application in patients. Several cell surface molecules have
been identiﬁed as targets for expanding Treg cells in vivo.
Here we describe a new approach to regulate GVHD by
manipulating Tregs ﬁrst in the donor and subsequently in
recipients post-HSCT via targeting two signaling pathways,
IL2-CD25 and TL1A-TNFRSF25.
First, we compared different protocols involving simul-
taneous and non-overlapping schedules by infusing IL-2
either free or complexed with anti-JES6mAb (IAC) and a
TL1A-Ig fusion protein (FP) into normal B6-FoxP3RFP mice.
A highly reproducible protocol was developed, wherein FP
was administered ﬁrst, followed by IAC. This routinely
resulted in w50% FoxP3+/CD4+ T cells, and also an overall
increase in the CD4/CD8 ratio in these animals versus
controls (3.7 vs. 1.5 in lymph node and 4.1 vs. 1.7 in splenic
T cells). Notably, expanded Tregs exhibited elevated CD25
expression and there was a 4-5x increase in the KLRG1+
fraction of FoxP3+CD4+ T cells. The expanded Treg popula-
tion in these mice diminished by 50% in the ﬁrst 4 days
following cessation of treatment and returned to normal
levels within 2 weeks. We then examined transplant
outcome after obtaining cells from these Treg expanded
mice as donors for an allogeneic, complete MHC-mis-
matched HSCT. Lymph node cells from Treg-expanded B6-
FoxP3RFP (H2b) mice were transplanted together with
normal TCD-BM into lethally conditioned BALB/c (H2d)
recipients. Recipients were treated with different regimens
of TL1A-Ig and/or free IL-2 (10,000 units/mouse) early
post-HSCT. Mice were monitored for weight change, clin-
ical score and survival. Treg frequencies were determined
in the blood and tissues 1 week post-HSCT. Initial TL1A-Ig
treatment of recipients following transplant with Treg
expanded donor T cells resulted in rapid lethality. These
observations were consistent with the known effector cell
co-stimulation via TNFRSF25 in the presence of antigen.
Only Treg expansion in the donor combined with initial IL-
2 followed by TL1A-Ig treatment of the recipient post-HSCT
resulted in amelioration of GVHD. In summary, a combi-
nation strategy employing the targeted signaling of CD25
and TNFRSF25 was identiﬁed which can markedly expand
Treg cells including a KLRG1+ population. Signaling via
TNFRSF25 followed by CD25 in T cell donors in conjunction
with the reverse targeting of these receptors in recipients
post-transplant resulted in attenuation of GVHD.464
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Figure 1. Cumulative incidence of HHV-6 in ATG and non-ATG recipients
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Background: Anti-thymocyte globulin (ATG) may be used
as part of the conditioning regimen in allogeneic stem
cell transplant to reduce severe graft-versus-host disease
(GVHD) and to improve engraftment. However, the use of
ATG in this setting has been associated with delayed
immune reconstitution that may lead to reactivation of
viral infections. Here, we investigated the effect of ATG
on the reactivation of multiple viral infections and the
incidence of acute and chronic GVHD in those who
received matched-unrelated donor (MUD), matched-
related donor (MRD) or double umbilical cord blood
transplants (CB).
Methods: We reviewed the medical records of 117 patients
undergoing allogeneic stem cell transplants at University
Hospitals Seidman Cancer Center between 2010 and 2013.The data collected include demographics, graft source, con-
ditioning regimen, ATG (types/total dose: rabbit: 3 mg/kg, 6
mg/kg or 7.5 mg/kg and equine: 60 mg/kg or 90 mg/kg),
GVHD prophylaxis regimen, viral infection status before and
after transplant, acute and chronic GVHD, death and relapse.
ATG was only administered to MUD and CB, but not MRD
recipients. The cumulative incidence of CMV, EBV, HHV-6 or
HHV-8 viremia (PCR copy > 1000), acute and chronic GVHD
was estimated with death as the competing risk. Two-sided
p-values2 0.05 were considered statistically signiﬁcant.
Serum viral load was prophylactically monitored by PCR
weekly.
Results: Of 117 allogeneic stem cell transplants, 39 were
MUD, 31 were MRD and 47 were CB. 77 transplants
received reduced-intensity conditioning regimen while
others were myeloablative. 12 graft failures were excluded
from the analysis. Among the remaining 105 transplants,
there was no signiﬁcant difference in the reactivation of
CMV, EBV or HHV-8 in patients treated with ATG
compared with patients not receiving ATG. Cumulative
incidence of HHV-6 reactivation was signiﬁcantly higher in
ATG recipients by day 100 post-transplant (42.9 vs 13.9,
p¼0.002) (Figure 1). HHV-6 reactivation in CB transplants
was higher as early as by day 30 when compared with
MUD or MRD recipients (43 vs 10.5 vs 6.7, p<0.0001). No
central nervous system manifestations of HHV-6 were
observed. Cumulative incidence for overall acute GVHD
and grade III-IV acute GVHD in patients receiving ATG and
those who did not by day 100 was 42.5 versus 50.6
(p¼0.128) and 4.8 versus 12.5 (p¼0.145), respectively. In
addition, cumulative incidence of chronic GVHD was lower
in the ATG group by day 365 (32.1 vs 55.6) although not
statistically signiﬁcant (p¼0.192).
Conclusion: ATG use as part of a conditioning regimen in our
allogeneic stem cell transplant cohort was associated with
post-transplant HHV-6 reactivation, but not CMV, EBV or
HHV-8 although the clinical signiﬁcance of this ﬁnding was
unclear.
